Rakuten Medical Initiates First-in-Human Phase 1 Trial of PD-L1-Targeted RM-0256 Photoimmunotherapy in Japan

On November 16, 2026 Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox platform-based photoimmunotherapy, reported that it has initiated a Phase 1 clinical trial of RM-0256 photoimmunotherapy in Japan. RM-0256, an anti-PD-L1 antibody-light-activatable dye conjugate, is the third drug candidate developed by Rakuten Medical based on its Alluminox platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study (RM-0256-101 / jRCT2031260118) is a first-in-human, open-label, non-controlled, dose-escalation trial that will enroll 24 patients with solid tumors, including malignant skin tumors, who are refractory to or ineligible for standard treatment. It is being conducted at Kobe University Hospital (Principal Investigator: Naomi Kiyota, M.D., Ph.D.), National Cancer Center Hospital (Principal Investigator: Noboru Yamamoto, M.D., Ph.D.), and National Cancer Center Hospital East (Principal Investigator: Akira Takahashi, M.D., Ph.D.).

The study is being funded by the Japan Agency for Medical Research and Development (AMED) to support the development of RM-0256 for advanced or recurrent malignant epithelial skin tumors, which are the initial target indication in this study.

The primary objectives of the study are to evaluate the safety and tolerability of RM-0256 photoimmunotherapy and to identify recommended drug and light doses for Phase 2 clinical development. Primary endpoints includes dose-limiting toxicities and adverse events. Secondary endpoints includes tumor response and pharmacokinetic parameters of RM-0256. Exploratory assessments will also evaluate biomarkers associated with RM-0256 photoimmunotherapy.

Background on PD-L1 and RM-0256
PD-L1 is an immune checkpoint protein expressed on tumor cells and on immunosuppressive cells in the tumor microenvironment, including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). The interaction of PD-L1 with PD-1 on activated T cells may suppress T-cell-mediated antitumor immune responses.

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway have become standard treatments for a variety of cancer types. However, there remains a need for novel treatment options for patients with highly immunosuppressed tumors or tumors that are resistant to ICIs.

RM-0256 is an antibody-dye conjugate comprising AB-256, a proprietary anti-PD-L1 monoclonal antibody developed by Rakuten Medical, and IRDye 700DX (IR700), a light-activatable dye. RM-0256 specifically binds to cells expressing PD-L1. In RM-0256 photoimmunotherapy, RM-0256 is administered intravenously, followed approximately 24 hours later by illumination of the targeted lesion with 690 nm laser light. The laser light transiently activates IR700, which, in preclinical studies, has been shown to induce necrosis or elimination of RM-0256-bound target cells.

Preclinical studies have suggested that RM-0256 photoimmunotherapy may act through three complementary mechanisms:

Elimination of PD-L1–expressing immunosuppressive cells;
Direct destruction of PD-L1-expressing tumor cells; and
Immune checkpoint blockade through inhibition of PD-L1/PD-1 interaction, potentially enhancing systemic antitumor immune responses.
About Alluminox platform
The Alluminox platform is Rakuten Medical’s investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical’s pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical’s Alluminox platform-based photoimmunotherapy is investigational.

(Press release, Rakuten Medical, NOV 16, 2026, View Source [SID1234674831])